The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.

Merck & Co’s Belsomra (suvorexant ... Last year, the FDA slapped new warnings on the labels of a range of insomnia drugs – including zolpidem – after reports of sleepwalking, sleep driving ...

On March 11, a formal complaint was submitted to US Trade Representative Jamieson Greer, urging the Trump administration to ...

A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data ...

The FDA approval is based on the results of the open-label KEYNOTE-224 trial ... strengthen the evidence for their drugs and support EU filings. Meanwhile, Merck/MSD and Eisai also recently ...

Organon pleasantly surprised me with its financial results for Q4 2024. Read why I believe OGN is an attractive stock for ...

Many men tolerate finasteride well, but some have complications including symptoms that persist after stopping the drug.

Trump’s demand for firms to relocate to the US could be a problem for Ireland as big pharma may be pushed to consider ...